Three Seasons Wealth LLC Purchases 1,265 Shares of Medpace Holdings, Inc. $MEDP

Three Seasons Wealth LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 322.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,657 shares of the company’s stock after buying an additional 1,265 shares during the period. Three Seasons Wealth LLC’s holdings in Medpace were worth $931,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Norges Bank purchased a new stake in Medpace in the second quarter worth $66,597,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Bares Capital Management Inc. lifted its position in shares of Medpace by 319.2% during the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock worth $49,302,000 after purchasing an additional 119,608 shares during the last quarter. Finally, Wasatch Advisors LP boosted its stake in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares of the company’s stock, valued at $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Mizuho set a $582.00 price target on shares of Medpace in a report on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Barclays upgraded shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a research note on Friday, March 6th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Stock Performance

NASDAQ MEDP opened at $480.19 on Wednesday. The company has a market cap of $13.63 billion, a PE ratio of 31.38, a P/E/G ratio of 2.21 and a beta of 1.44. The firm’s 50 day moving average price is $488.61 and its 200-day moving average price is $537.50. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.